The spectrum of neurological manifestations and genotype-phenotype correlation in Indian children with Gaucher disease.

Autor: Venkatachari M; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Chakraborty S; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Correa ARE; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Mishra P; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Kocchar KP; Department of Physiology, All India Institute of Medical Sciences, New Delhi, India., Kabra M; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Chakrabarty B; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Kalaivani M; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India., Sapra S; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Mishra P; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Gulati S; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India., Gupta N; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Jazyk: angličtina
Zdroj: American journal of medical genetics. Part A [Am J Med Genet A] 2023 Apr; Vol. 191 (4), pp. 1038-1043. Date of Electronic Publication: 2023 Jan 13.
DOI: 10.1002/ajmg.a.63115
Abstrakt: Gaucher disease (GD), one of the most frequent autosomal recessive lysosomal storage disorders, occurs due to bi-allelic pathogenic variants in the GBA1. Worldwide, the c.1448T>C (L483P) homozygous pathogenic variant is reported to be associated with neurological GD phenotype. Clinical distinction between GD1 and GD3 may be challenging due to subtle neurological features. Objective methods to evaluate neurological signs and saccades may help in early diagnosis. This study was conducted to assess the neurological phenotype, and its severity using a modified severity scoring tool (mSST), and the genotype-phenotype correlation. A total of 45 children aged 2 years 6 months to 15 years with a confirmed enzymatic and molecular diagnosis of GD with or without therapy were recruited. mSST tool was used to assess the severity of the neurological phenotype. A digital eye movement tracker (View Point Tracker) was used to assess eye movements. Clinical and genetic findings were analyzed. Out of 45 patients, 39 (86.7%) had at least one neurological phenotype detected using the mSST tool, with impairment of cognitive function (68.8%, 31/45) being the commonest feature. Thirty-two of 45 (71%) were assessed for saccadic eye movements using the eye tracker. Of these, 62.5% (20/32) had absent saccades. Four children (8.9%, 4/32) without clinical oculomotor apraxia had absent saccades on the viewpoint eye tracker. Overall, 77.7% (35/45), had homozygosity for c.1448T>C in GBA1 of which 91.4% (32/35) had neurological manifestations. Other alleles associated with neurological phenotype included c.1603C>T(p.R535C), c.1184C>T (p.S395F), c.115+1G>A (g.4234G>A), c.260G>A (p.R87Q) and c.1352A>G (p.Y451C). To conclude, in India, the c.1448T>C pathogenic variant in GBA1 is the commonest  and is associated with neurological phenotype of GD. Therefore, every patient of GD should be assessed using the mSST scoring tool for an early pick up of neurological features. The routine use of a viewpoint eye tracker in children with GD would be useful for early recognition of saccadic abnormalities.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: